The Latest

• April 13, 2020

  By Charleston Lim

  Cancer Drug Developed By Chinese Biotech BeiGene Gets Green Light

  BeiGene's anti-PD-1 antibody immunotherapy tislelizumab received regulatory approval to treat advanced or metastatic urothelial carcinoma.

  

  BeiGene's anti-PD-1 antibody immunotherapy tislelizumab received regulatory approval to treat advanced or metastatic urothelial carcinoma.
• November 06, 2019

  By Ritchelle Ann De Castro

  AstraZeneca To Invest $1 Billion On Chinese Health-Care Startups

  Beijing's new policy measures opened China up to investors interested in the country's biotechs.

  

  Beijing's new policy measures opened China up to investors interested in the country's biotechs.